Histone demethylase Jmjd3 regulates osteoblast differentiation via transcription factors Runx2 and Osterix

Di Yang 1,2, Hirohiko Okamura 1, Yoshiki Nakashima 1, Tatsuji Haneji 1

1Department of Histology and Oral Histology, Institute of Health Biosciences, The University of Tokushima Graduate School, Kuramoto, Tokushima 770-8504, Japan, 2Department of Endodontics, School of Stomatology, China Medical University, Shenyang 110002, China

Running Title: Regulation of osteoblast differentiation by Jmjd3

To whom correspondence should be addressed: Tatsuji Haneji, DDS, Ph.D., Department of Histology and Oral Histology, Institute of Health Biosciences, The University of Tokushima Graduate School, 3-18-15, Kuramoto, Tokushima 770-8504, Japan, Tel: 81-88-633-7321; Fax: 81-88-633-7342; E-mail: tat-hane@tokushima-u.ac.jp

Keywords: Jmjd3; H3K27me3; BMP-2; Osteoblast differentiation; Histone demethylation; Runx2; Osterix

Background: The roles of histone demethylase Jmjd3 in osteoblasts are not fully understood. Results: Jmjd3 expression increased during osteoblast differentiation. Silencing of Jmjd3 impaired osteoblast differentiation. Introduction of the exogenous Runx2 and Osterix partly rescued osteoblast differentiation in shJmjd3 cells. Conclusion: Jmjd3 regulates osteoblast differentiation via transcription factors Runx2 and Osterix. Significance: This manuscript provides new insights about the roles of Jmjd3 in osteoblast differentiation.

Abstract

Post-translational modifications of histones including methylation play important roles in cell differentiation. Jumonji domain-containing 3 (Jmjd3) is a histone demethylase, which specifically catalyzes the removal of trimethylation of histone H3 at lysine 27 (H3K27me3). In this study, we examined the expression of Jmjd3 in osteoblasts and its roles in osteoblast differentiation. Jmjd3 expression in the nucleus was induced in response to the stimulation of osteoblast differentiation as well as treatment of bone morphogenetic protein-2 (BMP-2). Either treatment with Noggin, an inhibitor of BMP-2, or silencing of Smad1/5, suppressed Jmjd3 expression during osteoblast differentiation. Silencing of Jmjd3 expression suppressed osteoblast differentiation through the expression of bone-related genes including Runx2, Osterix, Osteopontin, Bone sialoprotein (BSP), and Osteocalcin (OCN). Silencing of Jmjd3 decreased the promoter activities of Runx2 and Osterix and increased the level of H3K27me3 on the promoter regions of Runx2 and Osterix. Introduction of the exogenous Runx2 and Osterix partly rescued osteoblast differentiation in the shJmjd3 cells. The present results indicate that Jmjd3 plays important roles in osteoblast differentiation and regulates the expressions of BSP and OCN via transcription factors Runx2 and Osterix.

Introduction

Bone is a dynamic tissue that undergoes continuous remodeling through bone formation and resorption. Osteoblasts are responsible for bone formation while osteoclasts are responsible for bone resorption. Bone morphogenetic protein-2 (BMP-2) is a critical autocrine and paracrine growth factor for bone formation, which is produced by many types of cells including osteoblasts (1-3). BMP transduces its signal via the intracellular downstream mediators Smads. Upon activation of BMP pathway, Smad1 and
Smad5 are phosphorylated and interact with Smad4 to enter the nucleus to regulate their target genes including Runx2 and Osterix (4). Both Runx2 and Osterix are important transcription factors for osteoblast differentiation and control the expressions of bone-related genes such as Osteopontin (OPN), Bone sialoprotein (BSP), and Osteocalcin (OCN) (5-10). These bone-related genes are required for the terminal osteoblast differentiation and bone mineralization (11,12).

Eukaryotic DNA is packaged into chromatin whose basic repeating unit is a nucleosome. The nucleosome consists of packaged DNA and an octamer of the core histones, H2A, H2B, H3, and H4. Histones have their flexible tails extending from the nucleosomal core, which are subjected to numerous modifications such as methylation, acetylation, ubiquitination, and phosphorylation. These modifications change chromatin activity for gene transcription. Site-specific histone methylation on lysine (K), being either mono-(me1), di- (me2), or tri- (me3) methylation, enables the gene promoter region to be accessible or inaccessible for transcription factors. Histone methylation plays a pivotal role during cell commitment and differentiation in many types of cells (13-15). Trimethylation of histone H3 at lysine-4, -36, and -79 (H3K4, H3K36, and H3K79) is implicated in transcriptional activation, whereas trimethylation of histone H3 at lysine-9 and -27 (H3K9 and H3K27) is associated with transcriptional repression (16,17). Histone methylation has been demonstrated to be reversible and can be eliminated by demethylases (18,19).

Jumonji domain-containing 3 (Jmjd3) has been identified as a histone demethylase, which specifically catalyzes the removal of trimethylation of histone H3K27 (H3K27me3). Jmjd3 is regulated by a variety of differentiation cues and stress signals in macrophages (20), neuronal stem cells (21), and epidermal cells (22). In addition, Jmjd3-induced demethylation of H3K27me3 in the transcription start site of Nfatc1 gene plays a critical role in osteoclast differentiation (23). However, the roles of Jmjd3 in osteoblasts are not fully understood.

In this study, we examined the expression and subcellular localization of Jmjd3 in osteoblasts. Jmjd3 expression in the nucleus was induced during osteoblast differentiation. Silencing of Jmjd3 expression suppressed osteoblast differentiation and bone formation. Silencing of Jmjd3 also increased the level of H3K27me3 on the promoter regions of Runx2 and Osterix. Introduction of the exogenous Runx2 and Osterix recovered the osteoblast differentiation and expressions of BSP and OCN in the Jmjd3 knock-down cells. These findings indicate that Jmjd3 plays important roles in the osteoblast differentiation via Runx2 and Osterix transcription factors.

Experimental procedures

Materials

Alpha-modified Eagle’s minimal essential medium (α-MEM) was purchased from Invitrogen (Carlsbad, CA, USA). Plastic dishes were from IWAKI (Chiba, Japan) and fetal bovine serum (FBS) from JRH Biosciences (Lenexa, KS, USA). Antibody against Jmjd3 was purchased from Abcam (Cambridge, UK). Antibodies against H3K27me3, H3K4me3, H3K9me3, H3K36me3, and H3 were obtained from Takara (Kyoto, Japan). Anti-B23 and anti-Eps15 antibodies were from Santa Cruz Biotechnology (Dallas, TX, USA). Anti-Flag and anti-β-actin antibodies, ascorbic acid (ASA), β-glycerophosphate (β-GP), Fast Red TR, naphthol AS-MX phosphate, and calcein were purchased from Sigma-Aldrich (St. Louis, MO, USA). Atelocollagen was from KOKEN (Tokyo, Japan). The other materials used were of the highest grade commercially available.

Cell culture

Cells were cultured in α-MEM supplemented with 10% FBS (growth medium) at 37 °C under a humidified atmosphere of 5% CO₂. For the induction of osteoblast differentiation, the growth medium was supplemented with 50 μM ASA and 10 mM β-GP (osteoblast differentiation medium). For recombinant human BMP-2 treatment, cells were treated with 100 ng/ml of BMP-2 (R&D Systems, Minneapolis, MN, USA) in growth
medium. For the experiments using inhibitors, cells were pretreated with 100 ng/ml Noggin (R&D Systems), 100 nM U0126 (Cell Signaling Technology, Danvers, MA, USA), or 50 μM LY294002 (Promega, Madison, WI, USA) for 3 h and then cultured in the osteoblast differentiation medium for another 72 h.

RNA preparation and real-time PCR analysis
Cells were homogenized in Trizol reagent (Invitrogen), and total RNA was extracted according to the manufacturer’s protocol. Reverse transcription was carried out with Reverse Transcription Kit (Takara). Real-time PCR of each gene was performed in triplicate for at least 3 independent experiments with a 7300 Real-time PCR system (Applied Biosystems, Carlsbad, CA, USA) using SYBR Premix Ex Taq™ (Takara). The sequences of the primers were as follows:

- **Gapdh**:
  forward, 5’-TGTGTCCGTCTGGATCTGA-3’
  reverse, 5’-TTGCTGTGAAGTCGCAGGAG-3’
- **Jmjd3**:
  forward, 5’-CTGCTGTAACCCACTGCTGGA-3’
  reverse, 5’-GAAAGCCAATCATCACCCTTGTC-3’
- **Smad1**:
  forward, 5’-CTCAGCTTGCTGCCTTAAACAGAC-3’
  reverse, 5’-CCGTGGAGCGGATAAGACAGA-3’
- **Smad5**:
  forward, 5’-TGCAGCTTGACCGTCCTTACC-3’
  reverse, 5’-GCCATCGTCTGCTCTGCATC-3’
- **Runx2**:
  forward, 5’-CATTTGCACTGGGTCACACGTA-3’
  reverse, 5’-GAATCTGGCCATGTTTGTGCTC-3’
- **Osterix**:
  forward, 5’-CTTCCCAATCCTATTTGCCGTTT-3’
  reverse, 5’-CGGCCAGGTTCTAACAACCAATCT-3’
- **BSP**:
  forward, 5’-GAGCCTCGTGCCGACACTTA-3’
  reverse, 5’-AATTCTGACCCTCAGCCTTCATA-3’
- **OCN**:
  forward, 5’-CCGGGAGCAGTGTGAGCTTA-3’
  reverse, 5’-AGGCGGTCT TCAAGCCATACT-3’
- **OPN**:
  forward, 5’-TACGACCATGAGATTGAGTGA-3’
  reverse, 5’-TATAGGATCTGGGTGAGCTGTAA-3’
- **exogenous-Osterix**:
  forward, 5’-ATGGACTACAAGGACGACGC-3’
  reverse, 5’-CGGCCAGTACTAACCACTTCT-3’
- **exogenous-Runx2**:
  forward, 5’-AAAAGCCTGCTAACTGCAA-3’
  reverse, 5’-CCGGGCTGCTGAGGCTTGGAA-3’

SDS-PAGE and Western blot analysis
Cells were washed twice with phosphate-buffered saline (PBS) and then scraped into lysis buffer (1 mM DTT, 1 mM PMSF, 1 μg/ml leupeptin, 2 μg/ml aprotinin, 5 mM EGTA). The protein concentration was determined by using Protein Assay Reagent (Bio-Rad, Hercules, CA, USA) and diluted to a concentration of 1 mg/ml with lysate buffer. Twelve micrograms of each sample and pre-stained molecular weight marker were separated by SDS-PAGE and transferred to PVDF membranes (Millipore, Medford, MA, USA). The membranes were incubated for 2 h at ambient temperature in a blocking solution consisting of 5% non-fat skim milk in PBS containing 0.05% Tween-20 (PBS-Tween), washed briefly in PBS-Tween, and then incubated overnight at 4 °C in 5% non-fat skim milk in PBS-Tween containing specific antibodies (diluted at 1:1,000). After the membranes had been washed 4 times within 30 min in PBS-Tween, they were incubated at ambient temperature for 2 h in PBS-Tween containing horseradish peroxidase-conjugated secondary antibodies (diluted at 1:5,000). The membranes were then washed again as described above, and the proteins recognized by the antibodies were visualized with an ECL detection kit (Amersham Pharmacia Biotech,
for 5 min. The nuclear preparation was recovered and resuspended in the buffer containing 20 mM HEPES, pH 7.9, 15 mM MgCl₂, 0.42 M NaCl, 0.2 mM EDTA, 25% (v/v) glycerol, 1 mM DTT, and protease inhibitors, then centrifuged at 20,000×g for 5 min. The nuclear preparation was recovered in the supernatant, while the nuclear pellet was resuspended in the supernatant buffer containing 20 mM HEPES, pH 7.9, 15 mM MgCl₂, 0.42 M NaCl, 0.2 mM EDTA, 25% (v/v) glycerol, 1 mM DTT, and protease inhibitors, then centrifuged at 20,000×g for 5 min. The nuclear preparation was recovered in the supernatant. The coverslips were washed with PBS and mounted with fluorescent mounting medium (DakoCytomation, Carpinteria, CA, USA). The cells were examined under an Olympus BX50 microscope equipped with epifluorescence illumination using a U-MNIBA and a WU filter for green and blue fluorescence, respectively. Photomicrographs were recorded on a computer (Olympus, DP70-WPCXP). The blue color was reconstituted to the pseudo red color by using PP imager software (Olympus).

**Extraction of cytosolic and nuclear preparations**

For cytosolic and nuclear preparation, cells were lysed with hypotonic buffer (100 mM HEPES, pH 7.9, 15 mM MgCl₂, 100 mM KCl, 1 mM DTT, and protease inhibitors) and incubated on ice for 15 min. To the swollen cells in lysis buffer, 10% IGEPAL CA-630 solution was added and centrifuged at 11,000×g for 5 min. The cytosolic preparation was recovered in the supernatant, while the nuclear pellet was resuspended in the buffer containing 20 mM HEPES, pH 7.9, 15 mM MgCl₂, 0.42 M NaCl, 0.2 mM EDTA, 25% (v/v) glycerol, 1 mM DTT, and protease inhibitors, then centrifuged at 20,000×g for 5 min. The nuclear preparation was recovered in the supernatant.

**Small interfering RNA (siRNA) and short hairpin RNA (shRNA) transfection**

For transient silencing of Jmjd3, MC3T3-E1 cells were transfected with stealth siRNA targeting Jmjd3 (Invitrogen) with Lipofectamine 2000 (Invitrogen) (siJmjd3). Nonspecific siRNA (Invitrogen) was also transfected as a negative control (siCont). For establishment of stable Jmjd3 knock-down cells, MISSION® shRNA Lentiviral transduction particles for Jmjd3 (Sigma-Aldrich) were infected into the cells according to the manufacturer’s directions and selected stable clones via puromycin (5 μg/ml) treatment (shJmjd3). MISSION® Non-Target shRNA Lentiviral transduction particles were used as a negative control (shCont). The target sites were as follows:

- siJmjd3: 5’-GAGCCTGCTACTACTGCAACGAAT-3’;
- siSmad1: 5’-CCTGCTGGAGATCCATCTGCA-3’;
- siSmad5: 5’-CCCATGTTATATATTGCCGTGTTTG-3’;
- siCont: siRNA Negative Control Med GC Duplex #3 (12935-113, Invitrogen);
- shJmjd3: 5’-
  CCGGCCCTGTGTTTACAAGTGAGAAGCTCGAGTTCTCAGTAACGAACAGGTTTTTG-3’;
- shCont: 5’-
  CCGGCAACAGATGAAGAGCACCACCTCGAGTTGTTGCTCTTCTTTGTTTTT-3’

**Alkaline phosphatase (ALP) staining**

Cultured cells in the osteoblast differentiation medium for 7 days were fixed in 3.7% formaldehyde for 10 min, and stored at 4 °C in 100 mM cacodylic acid buffer (pH 7.4). The cells were then incubated at 37 °C with freshly prepared alkaline phosphatase substrate solution (100 mM Tris-maleate buffer (pH 8.4), 2.8% N, N-dimethylformamide (v/v), 1 mg/ml Fast Red TR, and 0.5 mg/ml naphthol AS-MX phosphate). The reaction was terminated after 30 min by removal of the substrate solution and washing with 100 mM cacodylic acid buffer.
ALP activity assay

Cultured cells in the osteoblast differentiation medium for 7 days were scraped into ice-cold 50 mM Tris-HCl buffer (pH 7.4), sonicated for 20 sec using a sonifer-cell disruptor (Model UR-20P; TOMY, Tokyo, Japan), and centrifuged at 10,000xg for 20 min at 4°C. The ALP activity in the supernatant was then determined using p-nitrophenyl phosphate as a substrate according to the manufacturer’s instructions. The ALP activity was normalized to protein content as measured by Protein Assay Reagent (Bio-Rad).

Mineral apposition and quantification

For Von Kossa staining, cells cultured for 14 days in the osteoblast differentiation medium were fixed in 3.7% formaldehyde for 10 min, washed in cacodylic acid buffer pH 7.4, incubated in saturated lithium carbonate, and subsequently incubated in 3% AgNO3 (w/v) for 30 sec under ultraviolet light. The cells were rinsed with water and air-dried. For Alizarin red staining, cells cultured for 14 days in the osteoblast differentiation medium were washed twice with PBS, fixed in 3.7% formaldehyde for 10 min, and then stained with 0.1% Alizarin red (Sigma-Aldrich) at pH 6.3 for 10 min. For calcium measurement, cell lysates were collected in lysate buffer (100 mM Tris-HCl, pH 7.5) from the cells cultured for 21 days in the osteoblast differentiation medium and used for calcium measurement by using the calcium assay kit (Cayman, Ann Arbor, MI, USA). According to the manufacturer’s directions, the reaction was measured spectrophotometrically at 590 nm. Calcium content was normalized to protein content measured by Protein Assay Reagent (Bio-Rad).

Animal studies

All mice studied were reared in our specific pathogen-free mouse colony and given food and water ad libitum. Experiments were humanely conducted under the regulation and permission of the Animal Care and Use Committee of the University of Tokushima, Tokushima, Japan (toku-dobutsu 10051). For local injection, equal volume of atelocollagen and siRNA (siCont or siJmd3, 10 μM final concentration) were mixed on ice. Fifty μl of the mixture was injected subcutaneously into the calvarial region on day 3 and day 7 after birth. Briefly, a 27-gauge needle was inserted at the base of the calvaria and pushed until it reached to the central region of the skull. Solution was then injected over the parietal region of the skull. To measure bone mineralization rate, the mice were injected with calcein at concentration of 20 mg/kg on day 6 and day 10 after birth as described above. On day 12, mice were sacrificed and calvaria were dissected.

Microcomputed tomography (µCT) analysis of bone

Dissected mice calvaria were fixed and analyzed by a µCT system (Latheta LCT-2000, Aloka, Tokyo, Japan). Bone mineral density (mg/cm³) was also calculated by µCT analysis.

Histological analysis

After using for µCT analysis, dissected mice calvaria were embedded in plastic and sectioned at 7 μm. Sections were observed as green fluorescence given from calcein labeling. Trichrome staining was performed using Masson-Goldner staining kit (Merck, Darmstadt, Germany) according to the manufacturer’s directions. Von Kossa staining was achieved by incubation with 3% silver nitrate for 5 min, soda formol solution for 5min, 5% sodium thiosulfate for 5 min and counterstaining with Van Gieson solution for 3 min.

Reporter constructs and Luciferase assay

Osterix promoter -355/+91 and -786/+91 reporters were kindly gifted from Drs. Tohmonda and Horiuchi (Keio University, Japan). To clone the 5' upstream region of Runx2 gene, -625 to +1 of the Runx2 gene were amplified by PCR from DNA extracted from MC3T3-E1 cells. PCR product was digested with XhoI and Hind III and inserted into the pGL3 basic luciferase reporter vector (Promega). Three copies of Runx2 binding site “AACCACA” were inserted into the pGL3 basic luciferase reporter vector (Promega) and the recombinant plasmid was designated as Runx2
3×binding site. For luciferase assays, 70-80% confluent cells in 24-well dishes were transfected with 0.5 μg of promoter reporter vector using Lipofectamine LTX™ reagent (Invitrogen) according to the manufacturer’s directions. The cells were also co-transfected with 0.05 μg of pTK-Renilla (Promega) to normalize for transfection efficiency. pGL3 basic vector (Promega) was used for empty vector as control. After 24 h post-transfection, total cell lysates were prepared using Dual-Glo® Luciferase Assay System (Promega) and assessed for luciferase activity.

Chromatin Immunoprecipitation (ChIP) assay
ChIP assay was carried out using previously described procedures (24). Briefly, the shCont and shJmjd3 cells were cultured for 3 days in the osteoblast differentiation medium and chemically cross-linked with 1% formaldehyde for 15 min at ambient temperature. Cells were lysed, sonicated, and immunoprecipitated with 4 μg antibodies pre-absorbed with 40 μl protein A beads overnight at 4 °C. After several washes, the complexes were eluted and the cross-linking was reversed by overnight incubation at 65 °C. Extracted (input) and immunoprecipitated DNA was then purified by the treatment with RNase A, proteinase K, and multiple of phenol: chloroform: isooamyl alcohol. PCR was performed with the primers corresponded to the promoter regions of Runx2 and Osterix as follows:
Runx2 promoter primers 1:
forward, 5'-AAGGAGTTTGGCAAGCAGAC -3';
reverse, 5'-CAACTGAGTGTGGCGTTC -3';
Runx2 promoter primers 2:
forward, 5'-GCTCCTCTCCCTTCCCTTCC -3';
reverse, 5'-TGTCCTCTCCCTTCCCTTCC -3';
Osterix promoter primers 1:
forward, 5'-CAGAGATCTAGTGTGGCATGC -3';
reverse, 5'-GCTGCTGAGGAAAGGAACAG -3';
Osterix promoter primers 2:
forward, 5'-GAAGCTCTGACAACTTGCCC -3';
reverse, 5'-AAGGAGAGGGAGGGGAGGAAT -3'

Transfection
The shJmjd3 cells at 70-80% confluence were transfected with Flag-Osterix expression vector (25) or Runx2 (Promega, Flexi Halo Tag clone pFN21AB9739) expression vector using Lipofectamine LTX™ Reagent (Invitrogen) according to the manufacturer’s instructions. The pcDNA3.1 Flag empty vector transfection was used as negative control. After 2 days incubation, the cells were examined by immunocytochemistry, mineral apposition and quantification, and real-time PCR described above.

Statistical analysis
Each series of experiments were repeated at least three times and all the data were expressed as mean values ± SEM. Statistical analyses were performed by analysis of variance (ANOVA). Statistical significance was indicated with (*p value <0.05) or (**p value <0.01).

Results
Jmjd3 expression increased during osteoblast differentiation
The level of Jmjd3 mRNA expression in MC3T3-E1 cells cultured in the osteoblast differentiation medium increased in a time-dependent manner, as determined by real-time PCR (Fig. 1A). From Western blot analysis, the intensity of a band corresponding to Jmjd3 increased while that of H3K27me3 decreased during osteoblast differentiation (Fig. 1B). The levels of β-actin and H3, used as internal controls, did not change during the culture-period (Fig. 1B).

BMP-2 induced Jmjd3 expression in osteoblasts
To examine the effect of BMP-2 on Jmjd3 expression, MC3T3-E1 cells were treated with 100 ng/ml of BMP-2 for 72 h. BMP-2 stimulated the expression of Jmjd3 in a time-dependent manner, as determined by real-time PCR (Fig. 2A). Expression of Jmjd3 protein also increased while that of H3K27me3 decreased in MC3T3-E1 cells treated with BMP-2 (Fig. 2B). We further examined whether BMP-2 signaling would be involved in the Jmjd3 expression in MC3T3-E1 cells cultured in the osteoblast differentiation medium. Cells were pretreated for 3 h with 100
expressing shRNA specific for Jmjd3 were established by transfection into MC3T3-E1 cells, which are transducers of BMP-2 signal, also decreased Jmjd3 expression in the cells treated with BMP-2 (Figs. 2E, 2F, and 2G).

**Nuclear localization of Jmjd3 in osteoblasts**

To determine the localization of Jmjd3 in osteoblasts, MC3T3-E1 cells were cultured for 7 days in the osteoblast differentiation medium or treated with BMP-2 for 3 days. The cells were fixed, permeabilized, and stained with anti-Jmjd3 antibody. In the untreated cells, Jmjd3 was mainly localized in the cytosol. However, in the cells cultured in the osteoblast differentiation medium or treated with BMP-2, Jmjd3 was mainly detected in the nucleus (Fig. 3A). To confirm the localization of Jmjd3 in the nucleus, nuclear and cytoplasmic fractions were prepared from MC3T3-E1 cells treated with BMP-2 and analyzed by Western blotting. Figure 3B shows that the level of Jmjd3 protein increased in the nuclear fraction in the cells treated with BMP-2. The purity of nuclear and cytoplasmic fractions was confirmed by the presence of B23 and Eps15, respectively. Localization of Jmjd3 indicates that the Jmjd3 expression in the nucleus was induced during osteoblast differentiation.

**Silencing of Jmjd3 expression impaired differentiation and mineralization in osteoblasts**

To examine the role of Jmjd3 in osteoblast differentiation, gene silencing experiments were performed. Transient silencing of Jmjd3 by siRNA transfection into MC3T3-E1 cells markedly suppressed the expressions of Runx2 and Osterix compared with those in the siCont cells, as determined by real-time PCR (Fig. 4). The stable Jmjd3 knock-down MC3T3-E1 cells were established by infecting the lentivirus expressing shRNA specific for Jmjd3 (shJmjd3). MC3T3-E1 cells infected with nonspecific shRNA were used as a control (shCont). As expected, the expression of Jmjd3 significantly decreased in the shJmjd3 cells compared with that in the shCont cells, as determined by real-time PCR (Fig. 5A) and Western blot analysis (Fig. 5B). There are no differences in the rate of cell proliferation in shCont and shJmjd3 cells (data not shown). Figure 5B also shows that shJmjd3 cells displayed increased level of H3K27me3, whereas the levels of H3K4me3, H3K9me3, and H3K36me3 were unaffected. The levels of β-actin and H3 did not change in these cells (Fig. 5B).

To further clarify the role of Jmjd3 in osteoblast differentiation, shCont and shJmjd3 cells were cultured for the indicated periods in the osteoblast differentiation medium and ALP expression and mineralization were assessed by ALP, Von Kossa, and Alizarin red staining (Fig. 6A). The intensity of these staining decreased in the shJmjd3 cells compared with that in the shCont cells. In accordance with the staining results, ALP activity and calcium level were significantly decreased in the lysate from the shJmjd3 cells (Figs. 6B and 6C, respectively). To investigate the molecular mechanism in the impaired osteoblast differentiation by Jmjd3 silencing, the expression of several bone-related genes were examined in the shCont and shJmjd3 cells by real-time PCR. As shown in Figure 6D, the expressions of Runx2, Osterix, OPN, BSP, and OCN decreased in the shJmjd3 cells compared with those in the shCont cells.

**Local administration of siJmjd3 suppressed bone formation in mouse calvaria**

To examine the role of Jmjd3 in bone formation in vivo, we subcutaneously administrated the mixture of siJmjd3 with atelocollagen into the calvarial region of mouse. Local administration of siJmjd3 suppressed bone formation in mouse calvaria, as demonstrated by 3-dimension μCT images (Fig. 7A). Cortical bone mineral density (BMD) was lower in siJmjd3-injected mice versus siCont-injected ones (Fig. 7B). Goldner’s trichrome staining and Von Kossa staining showed that calvaria from the siJmjd3-injected mice had a
decrease in bone thickness with lower mineralization compared with those of siCont-injected mice. Injection of calcein twice at 4-day intervals indicated dynamic changes in bone mineral apposition. The distance between two consecutive labels in the calvaria was dramatically decreased in the siJmjd3-injected mice compared with that of the controls (Fig. 7C).

**Jmjd3 mediates the level of H3K27me3 on the promoter regions of Runx2 and Osterix**

To study the mechanisms responsible for the suppression of osteoblast differentiation in shJmjd3 cells, we first examined the promoter activity of transcription factors, Runx2 and Osterix. The schematic illustrations of Runx2 and Osterix promoter regions were shown in Figs. 8A and 8B, respectively. The luciferase activity of Runx2 (-625) and Osterix (-786 and -355) promoters as well as Runx2 3×binding site decreased in shJmjd3 cells (Figs. 8C and 8D). To assess whether the decreased activity could be resulted from the changes of histone modification on the promoter region, ChIP assay was performed using anti-H3K27me3 antibody and the primers amplifying the regions of Runx2 and Osterix promoter as indicated in Figs. 8A and 8B. The corresponding bands were detected in the samples from shJmjd3 cells, but not in the shCont cells (Figs. 8E and 8F). Input DNA and anti-IgG antibody-precipitated DNA were used as positive and negative controls, respectively.

**Introduction of exogenous Runx2 and Osterix rescued osteoblast differentiation in shJmjd3 cells**

To examine whether overexpression of Runx2 and Osterix could rescue the impaired osteoblast differentiation in the shJmjd3 cells, Runx2 and Osterix expression vectors were transfected into shJmjd3 cells. The expression of exogenous Runx2 was confirmed by real-time PCR (Fig. 9A). The density of ALP, Von Kossa, and Alizarin red staining and ALP activity were higher in the shJmjd3 cells transfected with Runx2 expression vector (Runx2), compared with mock transfected cells (mock) (Figs. 9B and 9C). The expressions of Osterix, BSP, and OCN increased in the Runx2 expression vector transfected cells (Fig. 9D).

Exogenous Osterix expression was also confirmed by immunostaining using anti-Flag antibody and real-time PCR (Figs. 10A and 10B). Compared with the cells transfected with the empty vector (Flag), Osterix expression vector-transfected cells exhibited increased density of ALP, Von Kossa, and Alizarin red staining, ALP activity, and expressions of BSP and OCN (Figs. 10C-10E).

**Discussion**

In this study, we provide the evidence that Jmjd3 is a novel factor responsible for osteoblast differentiation. The Jmjd3 expression was induced during osteoblast differentiation, which was mediated by BMP-2 signaling. Moreover, silencing of Jmjd3 decreased ALP activity and the expression levels of bone-related genes through the modification of H3K27me3 on the promoter regions of Runx2 and Osterix, resulting in the suppression of osteoblast differentiation and mineralization.

First, we showed that the Jmjd3 expression increased in the osteoblasts cultured in the osteoblast differentiation medium containing ASA and β-GP. Treatment of ASA and β-GP has been reported to induce BMP-2 expression in osteoblasts, which is required for osteoblast-specific gene expression (26-28). We examined whether the induced BMP-2 would mediate the Jmjd3 expression in the cultured cells. Noggin is an extracellular antagonist of BMP-2, which binds to BMP-2 and prevents its downstream signaling pathway. Noggin inhibited the Jmjd3 expression in the cells cultured in the osteoblast differentiation medium. In contrast, U0126 (MAPK inhibitor) and LY294002 (PI3K inhibitor) did not inhibit the Jmjd3 expression, although MAPK and PI3K pathways are involved in osteoblast differentiation (29,30). Furthermore, silencing of Smad1/5 decreased Jmjd3 expression, which suggests that BMP-2 signaling is involved in the induction of the Jmjd3 expression during osteoblast differentiation.

Second, we demonstrated that the induced Jmjd3 was mainly localized in the nucleus in the differentiating osteoblasts. In the untreated cells, the slight expression of Jmjd3 was observed in the cytoplasm. Expression of Jmjd3 in the nucleus
increased during osteoblast differentiation, as determined by immunocytochemistry and Western blot analysis. It was reported that Jmjd3 is localized in the nucleus during embryo development and neural stem cell differentiation (31,32). Induction of Jmjd3 expression in the nucleus suggests that Jmjd3 plays important roles in osteoblast differentiation as a histone demethylase.

Third, we examined the roles of Jmjd3 in osteoblast differentiation. With this objective, we performed the gene-silencing experiments by siRNA and shRNA. Transient knock-down of Jmjd3 decreased the expressions of Runx2 and Osterix, which are the markers at the earlier stage of osteoblast differentiation. To further investigate the role of Jmjd3 in the late stage of osteoblast differentiation and mineralization, stable Jmjd3-knock-down cells were established. Knock-down of Jmjd3 decreased the level of H3K27me3 but did not affect H3K4me3, H3K9me3, and H3K36me3, which is consistent with the other reports about the role of Jmjd3 as demethylase specific for H3K27me3 (33-35). In this study, we demonstrated that ALP activity and mineralization were dramatically reduced in the shJmjd3 cells, indicating that reduction of Jmjd3 expression strongly suppressed osteoblast differentiation. The impaired osteoblast differentiation was accompanied with significant decreases in the expressions of BSP, OCN, and OPN in the shJmjd3 cells. To further clarify the role of Jmdj3 in bone formation in vivo, we subcutaneously injected the siJmjd3 in the mouse calvarial region. Administration of siJmjd3 decreased bone mineral density, bone mineralization rate, bone thickness, and mineralized bone matrix. Taken together, silencing of Jmjd3 impaired osteoblast differentiation and bone formation.

Modifications of histones have several important consequences. The most profound effect of methylation of histones is their ability to cause compaction of the chromatin or facilitate access to the DNA, negatively or positively regulating the transcriptional activity of the target genes. Our study also uncovered a distinct promoter behavior in response to H3K27me3 occupation. Knock-down of Jmjd3 decreased the activity of Runx2 and Osterix promoters, as well as Runx2 3× binding site and increased the level of H3K27me3 on the promoter regions of Runx2 and Osterix. On the promoter regions of Runx2 and Osterix, there are several important binding sites for transcription factors such as Msx-2 and distal-less homeobox 5 (Dlx-5). Our results suggest that knock-down of Jmjd3 failed to remove the repressive transcription mark H3K27me3 on the promoter regions of Runx2 and Osterix, which further prevented Msx-2 and Dlx-5 from approaching to these binding sites, resulting in the downregulation of Runx2 and Osterix.

To further confirm the roles of Runx2 and Osterix in the Jmjd3 knock-down cells, we transfected Runx2 and Osterix expression vectors in the shJmjd3 cells. Introduction of the exogenous Runx2 and Osterix rescued osteoblast differentiation and the expressions of BSP and OCN in the shJmjd3 cells. These results indicate that Jmjd3 regulates the expressions of BSP and OCN during osteoblast differentiation via transcription factors, Runx2 and Osterix.

Recently, it was reported that histone demethylases such as NO66 (36) and retinoblastoma binding protein 2 (RBP2) (37) are involved in osteoblast differentiation. NO66, a histone demethylase of H3K4me and H3K36me, directly interacts with Osterix, which is required for the inhibition of Osterix transcriptional activity. RBP2 is also a histone demethylase of H3K4me and associates with Runx2, which in turn controls osteoblast differentiation. The targeted sites (H3K4 and H3K36) of NO66 and RBP2 are normally associated with the active gene transcription when the sites are methylated. Knock-down of NO66 and RBP2 has been reported to lead to the accelerated osteoblast differentiation. On the other hand, the target site of Jmjd3 is H3K27me3, which is generally relevant in the transcriptional repression. It is reasonable that knock-down of Jmjd3 resulted in the impaired osteoblast differentiation. The expression of ubiquitously transcribed tetratricopeptide repeat X chromosome (Utx), another demethylase of H3K27me3, also increased during osteoblast differentiation and knock-down of Utx gene decreased the expression of bone-
related gene including Runx2 and Osterix (unpublished data). These results support the view that H3K27me3 is important epigenetic regulators of osteoblast differentiation.

In summary, we demonstrated that Jmjd3 expression and nuclear localization were stimulated during osteoblast differentiation, which was mediated by BMP-2 signaling pathway. Silencing of Jmjd3 expression suppressed osteoblast differentiation through increasing occupation of H3K27me3 to the promoter region of Runx2 and Osterix. Introduction of exogenous Runx2 and Osterix partly recovered the expressions of BSP and OCN and sequentially osteoblast differentiation in the Jmjd3 knock-down cells. Our present study provides new findings that Jmjd3 plays important roles in osteoblast differentiation and regulates the expressions of BSP and OCN via transcription factors Runx2 and Osterix.

References


**Footnotes**

We thank Dr. K. Ochiai for constructing 3D images of mouse calvaria and Dr. J. Teramachi for his valuable discussions. We would like to give our gratitude to Drs. T. Tohmonda and K. Horiuchi for providing us with the Osterix promoter reporter vectors. We also thank Mrs. E. Sasaki for her skilful technical assistance. This study was supported by grants from the Grant-in-Aid for Scientific Research
from the Ministry of Education, Science, Sports, and Culture of Japan (21592330, 23592703, and 25462859).

**Figure legends**

**Figure 1.** The expression of Jmjd3 in osteoblasts. MC3T3-E1 cells were cultured in the osteoblast differentiation medium for the indicated periods. (A), The expression of Jmjd3 was examined by real-time PCR. (B), The protein expression of Jmjd3 and H3K27me3 were examined by Western blot analysis. The relative expression of Jmjd3/β-actin and H3K27me3/H3 were calculated by computer software (Image J). All the results in the real-time PCR are presented as means ± SEM. *P<0.05, **P<0.01

**Figure 2.** BMP-2 induced Jmjd3 expression in osteoblasts. MC3T3-E1 cells were treated with 100 ng/ml of BMP-2 for the indicated periods. The expression levels of Jmjd3 and H3K27me3 were examined by real-time PCR (A) and Western blot analysis (B). MC3T3-E1 cells were pretreated with 100 nM U0126, 50 μM LY294002, or 100 ng/ml of Noggin for 3 h and cultured for another 72 h in the osteoblast differentiation medium. Jmjd3 expression was examined by real-time PCR (C) and Western blot analysis (D). MC3T3-E1 cells were transfected with siRNA for Smad1 or Smad5 and cultured in the medium containing 100ng/ml of BMP-2 for another 72 h. The expressions of Smad1 (E), Smad5 (F), and Jmjd3 (G) were examined by real-time PCR. The relative expression of Jmjd3/β-actin and H3K27me3/H3 was calculated by computer software (Image J). All the data in the real-time PCR are presented as means ± SEM. *P<0.05, **P<0.01.

**Figure 3.** Nuclear localization of Jmjd3. (A), MC3T3-E1 cells were cultured for 7 days in the osteoblast differentiation medium or treated with 100 ng/ml of BMP-2 for 72 h. The localization of Jmjd3 was determined by immunocytochemistry. (B), MC3T3-E1 cells were treated without (Control) or with 100 ng/ml of BMP-2 (BMP-2). Seventy two hours later, the nuclear and cytoplasmic fractions were prepared. Western blot analysis was performed using the specific antibodies for Jmjd3, B23, and Eps15. The relative expression of Jmjd3/B23 or Eps15 was calculated by computer software (Image J). C, cytosolic fraction; N, nuclear fraction

**Figure 4.** Suppression of Runx2 and Osterix expression in Jmjd3 transient silencing cells. MC3T3-E1 cells were transfected with non- (siCont) or Jmjd3- (siJmjd3) specific siRNA and cultured for 3 days in the osteoblast differentiation medium. RNA was extracted and real-time PCR was performed for Jmjd3, Runx2, and Osterix. All the data are presented as means ± SEM. *P<0.05, **P<0.01.

**Figure 5.** Establishment of stable Jmjd3 knock-down cells. MC3T3-E1 cells were transfected with non- (shCont) or Jmjd3- (shJmjd3) specific shRNA and cultured for 3 days in the osteoblast differentiation medium. (A), The expression levels of Jmjd3 mRNA were examined by real-time PCR. Data are presented as means ± SEM. **P<0.01. (B), Western blot analysis was performed using the specific antibodies for Jmjd3, β-actin, H3K27me3, and H3. The relative expression of Jmjd3/β-actin and H3K27me3/H3 were calculated by computer software (Image J).

**Figure 6.** Inhibition of osteoblast differentiation by Jmjd3 silencing. (A), The shCont and shJmjd3 cells were cultured in the osteoblast differentiation medium for 7 and 14 days, respectively. The cells were stained for ALP expression (left panel) or for mineralization by Von Kossa (central panel) and Alizarin red (right panel). (B), The shCont and shJmjd3 cells were cultured for 7 days in the osteoblast differentiation medium and ALP activity was measured. (C), The shCont and shJmjd3 cells were cultured
for 21 days in the osteoblast differentiation medium and the calcium levels in the cultured cells were quantified. (D), The shCont and shJmjd3 cells were cultured in the osteoblast differentiation medium. The mRNA expressions of Runx2 and Osterix were determined on day 3 and those of OPN, BSP, and OCN were on day 7 by real-time PCR with normalization by Gapdh expression. Each bar represents the mean ± SEM. **P<0.01.

**Figure 7.** Local administration of siJmjd3 suppressed bone formation in mouse calvaria. (A), Three-dimension μCT images of calvaria from mice (12-day-old, n=4 for siJmjd3 injection, n=4 for siCont injection) injected with siCont or siJmjd3. (B), Cortical bone mineral density (BMD) of calvaria was determined by μCT. Data are presented as means ± SEM. **P<0.01. (C), Upper: Plastic sections of dissected mouse calvaria were examined under a fluorescence microscope. The distance between two calcein labeling layers reflect the bone mineralization rate. Middle: Sections of dissected mice calvaria were stained with Goldner’s trichrome to visualize bone thickness. Lower: Sections of dissected mice calvaria were stained with Von Kossa to visualize bone mineralization.

**Figure 8.** Knock-down of Jmjd3 suppressed the transcriptional activity of Runx2 and Osterix. (A and B), Schematic illustration of the promoter regions of Runx2 and Osterix. The context of luciferase reporter vectors and primers used for ChiP assay were indicated. (C and D), The activity of Runx2 promoter, Runx2 3xbinding site, and Osterix promoter were decreased in shJmjd3 cells. (E and F), Knock-down of Jmjd3 increased the level of H3K27me3 on the Runx2 (E) and Osterix (F) promoters. The shCont and shJmjd3 cells were cultured for 3 days in the osteoblast differentiation medium. Chromatin solution from the cells was subjected to ChIP analysis using anti-H3K27me3 and anti-IgG antibodies. PCR was performed with the primer pairs amplifying the promoter regions of Runx2 and Osterix. C, shCont; J, shJmjd3

**Figure 9.** Overexpression of Runx2 partly rescued osteoblast differentiation in the shJmjd3 cells. The shJmjd3 cells were transfected with Runx2 expression vector. (A), Expressions of exogenous and endogenous Runx2 were examined by real-time PCR. (B), Cells were cultured in the osteoblast differentiation medium for 7 days for ALP staining (left panel) and 14 days for Von Kossa (central panel) and Alizarin red staining (right panel). (C), Cells were cultured for 7 days in the osteoblast differentiation medium and ALP activity was measured. (D), The expressions of Osterix, BSP, and OCN were determined by real-time PCR. All the data in the real-time PCR experiments are presented as means ± SEM. *P<0.05, **P<0.01.

**Figure 10.** Overexpression of Osterix partly rescued osteoblast differentiation in the shJmjd3 cells. The shJmjd3 cells were transfected with empty vector (Flag) or Osterix expression vector (Flag-Osterix). (A), Transfected Osterix was confirmed by immunocytochemistry with anti-Flag antibody. (B), The exogenous and endogenous Osterix expressions were examined by real-time PCR. (C), Cells were cultured in the osteoblast differentiation medium for 7 and 14 days, respectively. The cells were stained for ALP expression (left panel) or for mineralization by Von Kossa (central panel) and Alizarin red (right panel). (D), Cells were cultured for 7 days in the osteoblast differentiation medium and ALP activity was measured. (E), The expressions of BSP and OCN were determined by real-time PCR. All the data in the real-time PCR experiments are presented as means ± SEM. *P<0.05, **P<0.01.